Valemetostat Tosylate
Phase 2ActiveInterest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Peripheral T-Cell Lymphoma
Conditions
Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Trial Timeline
Jun 3, 2021 → Feb 19, 2027
NCT ID
NCT04703192About Valemetostat Tosylate
Valemetostat Tosylate is a phase 2 stage product being developed by Daiichi Sankyo for Relapsed/Refractory Peripheral T-Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04703192. Target conditions include Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Peripheral T-Cell Lymphoma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07303387 | Phase 2 | Recruiting |
| NCT04842877 | Phase 2 | Active |
| NCT04703192 | Phase 2 | Active |
| NCT04102150 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Peripheral T-Cell Lymphoma